Law firm probes ACADIA investors' claims after trial misses key endpoint, stock drops sharply.

Pomerantz LLP is investigating potential securities fraud claims on behalf of ACADIA Pharmaceuticals investors following the company's announcement that its drug remlifanserin narrowly missed the primary endpoint in a Phase 2 trial for Alzheimer’s disease psychosis. The news caused ACADIA's stock to fall nearly 13% on September 24, 2026, and further declines after analyst downgrades. The investigation will determine if ACADIA or its executives engaged in unlawful practices related to the trial results disclosure. Investors affected are encouraged to contact the law firm for possible class action participation.

ACADIA Pharmaceuticals trades at USD 18.64 on Pluang as of Oct 14, 2026 04:11 WIB. The stock shows a 3.97% decline in one day, with a market cap of $3.41 billion. Investors hold ACAD shares for an average of 77 days on the platform.